HI-164OV

HI-164OV is an oral enteric-coated tablet vaccine containing inactivated, whole cells of non-typeable Haemophilus influenzae (NTHi), isolate 164, for the prevention and treatment of acute exacerbations in chronic obstructive pulmonary disease (COPD)[1]. It is designed to drive a specific T-cell immune response that promotes intrabronchial phagocytosis and down-regulates bronchial inflammation, potentially reducing the frequency and severity of COPD exacerbations[1][3]. The drug has been specifically studied in patients with moderate to severe COPD and a history of frequent exacerbations. The mechanism of action is immunostimulation, targeting the immune response to NTHi, a common bacterial pathogen in COPD exacerbations[1][3]. The developer is Hunter Immunology Pty Ltd.[1].

Other names

HI-164OV oral vaccine tabletHI164OV oral vaccine tabletHI 164OV oral vaccine tabletHI-164OV oral immunotherapeuticHI164OV oral immunotherapeuticHI 164OV oral immunotherapeutic